NCT04264715|UnknownDMC
Loading search results
Sponsor study identifier
interventional
824
1 country
1
Study Start
January 6, 2020
Actual (reported)Primary Completion
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Operating room S. aureus exposure has been directly linked to postoperative infections and is therefore an important target for infection prevention. Visible light (non-ultraviolet spectrum) at 405nm has been shown to be germicidal. We hypothesize that use of this light in operating rooms will reduce S. aureus transmission occurring within and between patients and reduce surgical site infections (SSIs). Visible light is safe for routine, continual exposure, and is less harmful than sunlight. We plan to install ambient, germicidal lighting in 4 operating rooms. This ambient light is not directly applied to patients (does not involve the surgical procedure lights). Patients will undergo surgery according to usual practice. We will conduct a case-control study where operating rooms with surgeries with the lights are matched to operating rooms with surgeries without lights. In Aim 1, 4 OR-pairs will be observed each day over an anticipated 103 working days for the primary outcome of S. aureus transmission events over a total minimum study period of 5.2 months (103 working days).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 6, 2020
Actual (reported)February 9, 2020
Actual (reported)February 11, 2020
Actual (reported)December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Staphylococcus aureus transmission rate
We will be assessing the transmission of bacteria to the patient during the case and from previous cases to subsequent cases.
sequential surgeries on the same 1 day
In this room, surgeries will be performed under ambient light including the wavelength 405nm
In this room, surgeries will be performed under ambient light from regular phosphorescent light does not include 405nm frequencies
In this room, surgeries will be performed under ambient light including the wavelength 405nm
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Northwestern Lake Forest Hospital
Lake Forest, Illinois, 60045, United States
First Submitted
February 9, 2020
First Posted
February 11, 2020
Study Start
January 6, 2020
Actual (reported)Primary Completion
December 31, 2020
Estimated (date passed)Eban II: Intervention for HIV Sero-Discordant Couples
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
February 12, 2020
Record last verified: 2020-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: